In late July, Sangamo’s former R&D chief Adrian Woolfson, who left the biotech when it split its R&D, launched its own gene therapy outfit. Replay’s primary platform was an HSV vector that, as a hub-and-spoke biotech, it said it built four different companies around.
Now the first of these four companies is out of the bag, with a co-founding team of four academics who have deep biotech experience. Under the name Eudora, the company Replay will address three eye diseases: retinitis pigmentosa, Stargardt disease and Usher syndrome type 1B.
Continue reading Endpoints with a free subscription
Unlock this story immediately and join over 1[ads1]52,500 biopharma professionals who read Endpoints daily – and it’s free.